Publicaciones en colaboración con investigadores/as de Harvard Medical School (52)

2023

  1. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

    Blood Advances

  2. The International Consensus Classification of myelodysplastic syndromes and related entities

    Virchows Archiv, Vol. 482, Núm. 1, pp. 39-51

2022

  1. Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROC-DRT registry

    Clinical Research in Cardiology, Vol. 111, Núm. 11, pp. 1276-1285

  2. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950

  3. Mood Disturbances Across the Continuum of Care Based on Self-Report and Clinician Rated Measures in the interRAI Suite of Assessment Instruments

    Frontiers in Psychiatry, Vol. 13

  4. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6

  5. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2025-2038.e1

  6. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2015-2024

2021

  1. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 6, pp. 2139-2144

  2. COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 5, pp. 2083-2086

  3. Efficacy and safety of percutaneous patent foramen ovale closure in patients with a hypercoagulable disorder

    Catheterization and Cardiovascular Interventions, Vol. 98, Núm. 4, pp. 800-807

  4. GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness

    Blood, Vol. 138, Núm. 17, pp. 1590-1602

  5. Identification of a locus near ULK1 associated with progression-free survival in ovarian cancer

    Cancer Epidemiology Biomarkers and Prevention, Vol. 30, Núm. 9, pp. 1669-1680

  6. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

  7. Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference

    Journal of Allergy and Clinical Immunology

  8. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 11, pp. 3918-3928

  9. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

    New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802

  10. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal

    HemaSphere, Vol. 5, Núm. 11, pp. E646

2020

  1. A reference map of the human binary protein interactome

    Nature, Vol. 580, Núm. 7803, pp. 402-408

  2. Effect of Residual Interatrial Shunt on Migraine Burden After Transcatheter Closure of Patent Foramen Ovale

    JACC: Cardiovascular Interventions, Vol. 13, Núm. 3, pp. 293-302